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OBJECTIVES The goals of this study were: 1) to assess the predictive value of baseline mitral flow pattern
(MFP) and its changes after loading manipulations as regards tolerance to and effectiveness
of beta-adrenergic blocking agent treatment in patients with chronic heart failure (CHF); and
2) to analyze the prognostic implications of chronic MFP modifications after beta-blocker
treatment.
BACKGROUND In patients with CHF, carvedilol therapy induces clinical and hemodynamic improvements.
Individual management, clinical effectiveness and prognostic implications, however, remain
unclear. The MFP changes induced by loading manipulations provide independent prognos-
tic information.
METHODS Echo-Doppler was performed at baseline and after loading manipulations in 116 consecutive
patients with CHF (left ventricular ejection fraction: 25  7%); 54 patients with a baseline
restrictive MFP were given nitroprusside infusion; 62 patients with a baseline nonrestrictive
MFP performed passive leg lifting. According to changes in MFP, we identified four groups:
17 with irreversible restrictive MFP (Irr-rMFP), 37 with reversible restrictive MFP
(Rev-rMFP), 12 with unstable nonrestrictive MFP (Un-nrMFP) and 50 with stable
nonrestrictive MFP (Sta-nrMFP). Carvedilol therapy (44  27 mg) was administered blind
to results of loading maneuvers. After six months, MFP was reassessed and patients
reclassified according to chronic MFP changes. During follow-up, tolerance to and effec-
tiveness of treatment and major cardiac events (death, readmission and urgent transplanta-
tion) were considered.
RESULTS Changes of MFP after loading manipulations were more accurate than baseline MFP in
predicting both tolerance to (p  0.01) and effectiveness of (p  0.05) carvedilol. After 26 
14 months of follow-up, cardiac events had occurred in 23/102 patients (23%). The event rate
in patients with chronic Irr-rMFP or Un-nrMFP was markedly higher than it was in those
with Rev-rMFP or Sta-nrMFP.
CONCLUSIONS In our patients, tolerance to and effectiveness of carvedilol was predicted better by
echo-Doppler MFP changes after loading manipulations than by baseline MFP. Chronic
changes of MFP after therapy are strong predictors of major cardiac events. (J Am Coll
Cardiol 2001;38:1675–84) © 2001 by the American College of Cardiology
Recent scientific evidence has allowed the construction of a
new pathophysiologic model of chronic heart failure
(CHF), which, putting aside the acute event, is character-
ized by the activation of neurohormonal mechanisms, which
can produce significant clinical consequences (1). The neg-
ative effects of increased sympathetic activity have adverse
biologic effects: alterations in intracellular calcium handling,
modification of the metabolic energy pathways and cardiac
myocyte death by necrosis and apoptosis (2–4). The inter-
stitial matrix also undergoes structural variations with an
increase of collagen deposition and subsequent formation of
fibrosis (5–7). These changes have negative functional
equivalents (8). Recent data have shown that baseline mitral
flow pattern (MFP) and its variations after loading manip-
ulations, recorded by means of echo-Doppler, are a powerful
prognostic marker in patients with CHF (9–11). Further-
more, scrupulous studies have provided evidence that vari-
ations of the left ventricular (LV) filling pattern over time
follow and describe the process of the LV remodeling
occurring in patients during the evolution of CHF (12–14).
Available data show that beta-adrenergic blocking agents
improve LV performance and symptoms, slow the progression
of CHF and reduce morbidity and mortality (15–18). Different
mechanisms have been suggested to explain how these drugs
induce beneficial effects on the remodeling process (19,20).
However, a variable percentage of subjects are intolerant, and it
is still unknown whether the same administration protocol
should be followed for all patients or whether individualized
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treatment strategies should be used. Whether the analysis of
the MFP could help to manage the titration therapy of
beta-blockers and predict their tolerance and effectiveness has
not yet been determined.
Accordingly, this study was performed to: 1) assess the
predictive value of baseline MFP as regards tolerance to and
effectiveness of beta-blocker treatment in a population of
patients with CHF; 2) evaluate whether acute changes of MFP
induced by loading manipulations may increase predictive
accuracy, and 3) analyze the prognostic implications of chronic
MFP modifications after treatment with beta-blockers.
METHODS
Patients. A total of 116 consecutive patients with CHF
caused by ischemic or idiopathic dilated cardiomyopathy
admitted to our heart failure unit for evaluation and treat-
ment of advanced heart failure were enrolled in the study.
Dilated cardiomyopathy was defined by two-dimensional
echocardiographic demonstration of a dilated LV (LV
end-diastolic volume index 78 ml/m2) with severe LV
systolic dysfunction (LV ejection fraction [LVEF]: 40%).
Patients who fulfilled the following criteria were entered
into the study: clinical stability 3 months; optimized oral
therapy; technically adequate Doppler echocardiographic
recordings, sinus rhythm on electrocardiogram; absence of
cardiac prosthetic valves or of any important regional
myocardial ischemia suitable for revascularization and a
clinical history without the normal contraindications to
beta-blockers. The patients were enrolled in the study after
having given informed consent.
Clinical, hemodynamic and Doppler echocardiographic
characteristics of the group, as well as therapeutic regimens,
are reported in Table 1.
STUDY PROTOCOL
The study was composed of the following three phases.
Baseline evaluation. CLINICAL AND FUNCTIONAL DETER-
MINATIONS. All patients underwent a complete physical
examination and New York Heart Association (NYHA)
functional class classification. Maximal exercise capacity was
evaluated during a symptom-limited cyclette exercise test by
Abbreviations and Acronyms
A  maximal velocity of late diastolic filling
AUC  area under the receiver operator
characteristic curve
CHF  chronic heart failure
CI  confidence interval
DT  deceleration time of early diastolic filling
E  maximal velocity of early diastolic filling
E/A  the ratio of maximal early to maximal late
diastolic filling velocities
MFP  mitral flow pattern
Irr-rMFP  irreversible restrictive mitral flow pattern
LV  left ventricle or left ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
Rev-rMFP  reversible restrictive mitral flow pattern
Sta-nrMFP  stable nonrestrictive mitral flow pattern
Un-nrMFP  unstable nonrestrictive mitral flow pattern
VO2  oxygen consumption
Table 1. Baseline Clinical, Doppler Echocardiographic and Hemodynamic Characteristics in All Patients and in the Patients Grouped
According to MFP
All Restrictive MFP Nonrestrictive MFP p Value
n 116 54 62
Age (yrs) 53  10 51  11 55  8 0.03
Gender (M/F) 94/22 43/11 51/11 0.72
Etiology (ischemic/idiopatic) 72/44 34/20 38/24 0.85
NYHA I to II/III to IV 80/36 25/29 55/7  0.001
Heart rate (beats/min) 80  13 84  14 77  11 0.008
Systolic pressure (mm Hg) 111  18 108  18 114  18 0.1
Peak VO2 (ml/min/kg) 14.8  4 14.4  4 15.1  4 0.41
LVEDD (mm) 72  10 72  10 72  10 0.87
LVESD (mm) 62  11 63  10 61  11 0.26
LVEF (%) 25  7 24  6 26  7 0.1
E (cm/s) 79  24 85  19 73  26
A (cm/s) 48  25 35  18 60  26
Deceleration time E (ms) 142  48 101  21 174  38
Mitral regurgitation (n [%]) 97 (84) 44 (81) 53 (85) 0.6
Cardiac index (l/min/m2) 2.3  0.5 2.1  0.5 2.4  0.4  0.001
Pulmonary wedge pressure (mm Hg) 19  9 24  3 13  5  0.001
Therapy
Diuretics (n [%]) 109 (94) 53 (98) 56 (90) 0.07
Digitalis (n [%]) 80 (69) 46 (85) 34 (55)  0.001
ACE inhibitors (n [%]) 105 (90) 50 (93) 55 (89) 0.48
Nitrates (n [%]) 62 (53) 32 (59) 30 (48) 0.24
Continuous variables are described as mean  SD.
A  late diastolic filling wave of mitral flow; E  early diastolic filling wave of mitral flow; E/A  early to late diastolic peak velocity ratio; LVEDD  left ventricular
end-diastolic diameter; LVESD  left ventricular end-systolic diameter; LVEF  left ventricle ejection fraction; MFP  mitral flow pattern; NYHA  New York Heart
Association class.
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measurements of peak oxygen consumption (VO2) (Medical
Graphics Corp., 2001 analyzer).
ECHOCARDIOGRAPHIC MEASUREMENTS. Echocardio-
graphic studies were performed using a Hewlett Packard
5500 ultrasound system with 2.5 MHz and 3.5 MHz
transducers. Doppler echocardiographic examinations were
performed at baseline and after six months. All images were
recorded on videotape and subsequently analyzed using the
software packages built into the ultrasound system. Doppler
velocity curves were recorded at a sweep velocity of
100 cm/s.
Left ventricular end-systolic and end-diastolic volumes
and dimensions and LVEF were assessed by apical four-
chamber views using the modified Simpson’s rule (21).
Images were accepted for analysis according to the guide-
lines proposed by Gordon when at least 80% of endocar-
dium was seen (22).
Mitral flow velocity was obtained from a two-
dimensional apical window with a pulsed wave technique by
placing the sample volume between the tips of the mitral
leaflets. The calculation of proximal accelerating flow was
performed using the method proposed by Bargiggia et al.
(23). The following parameters were calculated as averages
over five consecutive measurements: maximal velocity of
early (E) and late (A) diastolic filling, deceleration time
(DT) of early diastolic filling and the ratio of maximal early
to maximal late diastolic filling velocities (E/A) (24). We
identified, by our experience, two MFPs: 1) a restrictive
pattern when E/A was 1 and DT was 130, and 2) a
nonrestrictive pattern when E/A was 1 or E/A was 1
and DT was 130. According to these patterns, patients
were classified as, respectively, restrictive and nonrestrictive.
Loading manipulations. After recording MFP at baseline,
loading manipulations were performed. Specifically, in the
patients with restrictive MFP, nitroprusside was adminis-
tered by intravenous pump infusion at incremental doses of
0.5 g/kg per min every 5 min until a systolic arterial
pressure 80 mm Hg or pulmonary wedge pressure
15 mm Hg or patient’s discomfort were observed. At
maximal infusion dose in steady state condition, echo-Dopp-
ler examinations were again carried out. In the patients who
had a nonrestrictive MFP at baseline, the echo-Doppler
examinations were performed after passive lifting of the legs
to 45°. The MFP after both loading manipulations was
identified according to the same criteria as those used at
baseline.
The patients were then classified into four subgroups
according to baseline and acute response to loading manip-
ulations: 1) patients with irreversible restrictive MFP
(Irr-rMFP) (a baseline restrictive mitral flow that remained
restrictive after nitroprusside); 2) patients with reversible
restrictive MFP (Rev-rMFP) (a baseline restrictive mitral
flow that was restored to normal or pseudonormal MFP
after nitroprusside infusion); 3) patients with unstable non-
restrictive MFP (Un-nrMFP) (a baseline nonrestrictive
MFP that became restrictive after passive leg lifting); 4)
patients with stable nonrestrictive MFP (Sta-nrMFP) (a
baseline nonrestrictive MFP that remained so after passive
leg lifting).
Management of beta-blocker titration. Carvedilol ther-
apy was administered to all patients according to current
guidelines. The titration of this beta-blocker was performed
by a physician blinded to the results of the echo-Doppler
examinations. This phase could be continued after hospital
discharge in an outpatient setting. During the titration,
supplementary examinations (chest X-ray, echo-Doppler
and blood tests) were seldom carried out and therapeutic
variations (increase of diuretics or angiotensin-converting
enzyme inhibitor modifications) made accordingly. Patients
were defined “tolerant” when they had tolerated and com-
pleted the whole phase of titration.
Follow-up. All patients were followed-up with pro-
grammed clinical and functional evaluations, including
MFP assessment, every six months in our hospital. The
effectiveness of beta-blocker therapy after six months treat-
ment was examined from both clinical and instrumental
points of view. In particular, we considered the treatment
“clinically effective” when it improved NYHA functional
class and decreased cardiac events (cardiac mortality or
urgent heart transplantation or readmission for congestive
heart failure). Conversely, we considered the treatment
“instrumentally effective” when it was accompanied by a
greater improvement in LV performance than that expected
from chance alone due to intra- and interobserver variability
(25). In particular, LVEF, DT and mitral regurgitation
were considered improved if the change observed after six
months was respectively 4%, 11 ms and 4 mm
(proximal isovelocity surface area [PISA]).
In the period between two evaluations, the clinical status
of patients was monitored by intermittent telephone con-
tacts with the patient and his physician and by mailed
questionnaires.
Statistical analysis. Between-group comparisons of base-
line clinical and functional parameters were performed by
one-way analysis of variance for continuous variables and by
the chi-square test for categorical variables. Multiple com-
parisons were performed by the Tukey’s studentized range
test. Multivariate logistic regression analysis was used to
assess the prognostic value of baseline MFP in predicting 1)
tolerance to, and 2) effectiveness of beta-blocker therapy.
The same analysis was repeated using as predictor the MFP
change after loading manipulations, and the two predictive
models were compared by the rescaled generalized coeffi-
cient of determination (range of variation 0 to 1) (26) and by
the area under the receiver operator characteristic curves
(AUC) (27). Age, gender, etiology, NYHA class, LVEF
and peak VO2 were used in model building as adjusting
covariates. Covariance analysis was used to assess the asso-
ciation between MFP and beta-blocker dosage at the end of
the titration phase. For the purpose of prognostic evalua-
tion, chronic changes of MFP after six months of beta-
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blocker treatment were considered as predictors of the
combined outcome of cardiac mortality plus urgent heart
transplantation plus readmission for congestive heart failure.
Event-free distribution functions were estimated by the
Kaplan-Meier method. The association between predictor
variables and outcome was assessed by the Cox proportional
hazards regression model. All patients who died from
noncardiac causes and those who underwent elective cardiac
transplantation were considered as censored observations.
Prognostic information was expressed as relative risk with
95% confidence interval (CI). Descriptive statistics are
presented as mean  SD. A p value of 0.05 was
considered as statistically significant.
RESULTS
MFP findings. At baseline 54 patients had a restrictive
MFP, and 62 patients had a nonrestrictive MFP. These two
groups were not different in terms of LV dysfunction,
therapeutic regimen or exercise capacity (Table 1). How-
ever, patients who had a nonrestrictive MFP were in a lower
functional class and had a better hemodynamic profile than
patients with a restrictive MFP. A statistically significant,
albeit clinically insignificant, difference was observed in the
age of the two groups.
The two loading manipulations to evaluate diastolic
reserve (sodium nitroprusside test in the patients with a
restrictive MFP and passive leg lifting in the other patients)
were well tolerated without adverse events. After the sodium
nitroprusside test 17/54 (31%) patients did not change their
MFP and were allocated to subgroup 1 (Irr-rMFP). In the
remaining 37/54 (69%) patients, the MFP reverted to a
nonrestrictive form, and these patients were allocated to
subgroup 2 (Rev-rMFP). Clinical and instrumental findings
were similar in the two subgroups (Table 2), and no
differences were found in the maximal dose of nitroprusside
infusion (1.3  1.5 g/kg per min vs. 1.1  1.3 g/kg per
min, p  0.7). After the leg-lifting maneuver, 12/62 (19%)
patients developed a restrictive MFP and were allocated to
subgroup 3 (Un-nrMFP). The remaining 50/62 (81%)
patients maintained a nonrestrictive MFP and were allo-
cated to subgroup 4 (Sta-nrMFP). Overall, MFP changed
in 49/116 (42%) patients after strategies to assess the
diastolic reserve.
Management of beta-blocker titration. The mean dose of
carvedilol was 44  27 mg/day (range 6.25 to 150 mg/day).
Carvedilol administration was interrupted in 14/116 (12%)
patients because of the appearance of acute heart failure.
The titration was stopped in 88/116 (76%) patients when
the heart rate dropped below 50 beats/min and in 12/116
(10%) patients when asymptomatic arterial hypotension
developed. The titration duration was 42  19 days (14 to
120 days). During the titration phase, 37/116 (32%) pa-
Table 2. Clinical, Doppler Echocardiographic and Hemodynamic Characteristics in the Patients
Grouped According to Baseline MFP and Acute Change After Loading Manipulations
Restrictive MFP Nonrestrictive MFP
Irreversible Reversible Unstable Stable
n 17 37 12 50
Gender (M/F) 12/5 31/6 10/2 41/9
Age (yrs) 49  11 49  11 56  4 55  9
Etiology (ischemic/idiopatic) 11/6* 23/14* 3/9† 35/15
NYHA I to II/III to IV 7/10†* 18/19†* 10/2 45/5
Heart rate (beats/min) 89  15†* 82  12 72  12 79  11
Systolic pressure (mm Hg) 107  18 109  18 103  12 117  19
Peak VO2 (ml/min/kg) 14.3  3 14.5  5 15.2  5 15.1  4
LVEDD (mm) 71  10 73  10 73  11 72  10
LVESD (mm) 62  9 64  11 63  12 60  10
LVEF (%) 24  7 24  6 25  8 26  7
E (cm/s) 86  16 85  20 81  32 71  25
A (cm/s) 28  13 36  18 54  19 61  27
Deceleration time E (ms) 91  21 104  21 158  21 177  40
Mitral regurgitation (n [%]) 14 (82) 30 (81) 11 (91) 42 (84)
Cardiac index (l/min/m2) 1.9  0.4† 2.2  0.5† 2.3  0.4* 2.5  0.4*
Pulmonary wedge pressure (mm Hg) 27  5 25  5 13  5* 8  3*†
Therapy
Diuretics (n [%]) 16 (94) 36 (97) 11 (92) 45 (90)
Digitalis (n [%]) 15 (88)† 31 (84)† 7 (58) 28 (56)
ACE-inhibitors (n [%]) 14 (82) 35 (94) 11 (92) 45 (90)
Nitrates (n [%]) 9 (53) 23 (62) 8 (67) 22 (44)
Carvedilol (mg/day) 25  20 46  34‡ 25  14 57  32‡
Continuous variables are described as mean  SD.
*p  0.05 versus unstable nonrestrictive MFP; †p  0.05 versus stable nonrestrictive MFP; ‡p  0.05 versus restrictive
irreversible and unstable nonrestrictive MFPs.
A  late diastolic filling wave of mitral flow; E  early diastolic filling wave of mitral flow; LVEDD  left ventricular
end-diastolic diameter; LVEF  left ventricular ejection fraction; LVESD  left ventricular end-systolic diameter; MFP 
mitral flow pattern; NYHA  New York Heart Association class.
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tients were submitted to additional examinations; in 34/116
(29%) patients, therapeutic variations were made.
Figure 1 shows the titration profile according to baseline
MFP and its change after loading manipulations. The
management of beta-blocker titration was more complex in
the groups with a restrictive MFP at baseline than in the
groups with a nonrestrictive MFP. Patients with a baseline
restrictive MFP had a greater number of titration interrup-
tions compared with patients with a nonrestrictive pattern
(20% vs. 5%, p  0.02). Among restrictive patients, those
with an irreversible pattern after loading manipulations had
a much higher treatment interruption rate compared with
those with a reversible pattern (47% vs. 8%, p  0.001).
Conversely, among nonrestrictive patients, those with a
stable pattern after loading manipulations had a much lower
treatment interruption rate compared with those with an
unstable pattern (2% vs. 17%, p  0.03). Patients who had
a baseline restrictive MFP were more frequently submitted
to additional examinations and therapeutic variations than
those with a nonrestrictive pattern (46% vs. 19% and 44%
vs. 16%, p  0.002 and p  0.001, respectively). In the
subgroup with Irr-rMFP, 88% required additional exami-
nations and 82% therapeutic variations, while, in the sub-
group with Rev-rMFP, only 27% needed additional exam-
inations, and another 27% had therapeutic variations (p 
0.001 for both comparisons). Among nonrestrictive pa-
tients, only 10% of those with a stable pattern after loading
manipulations required additional examinations, and only
8% needed therapeutic variations, whereas the same proce-
dures were required, respectively, in 58% and 50% of
unstable patients (p  0.001 for both comparisons).
MFP as a predictor of tolerance to beta-blocker treat-
ment. Table 3 shows the results of the analysis of associa-
tion between MFP and tolerance to beta-blocker treatment.
For each aspect of tolerance (titration interruption, addi-
tional examinations and therapeutic variations), the upper
part of the respective panel above the dashed line shows the
multivariate predictive model using baseline MFP, whereas
the lower part shows the same analysis using the acute
change of MFP after loading manipulations. Among all
potential covariates considered in the analysis (age, gender,
NYHA class, etiology, LVEF and peak VO2), only NYHA
class reached statistical significance in predicting the need
for additional examinations or therapeutic variations. Of
note, in the prediction of therapeutic variations, baseline
MFP adjusted for NYHA class did not show statistical
significance, indicating that its predictive information was
already “contained” in the score of disease severity. It should
be stressed that, in all three models using diastolic reserve
information, the presence of a Rev-rMFP did not signifi-
cantly affect the prediction of beta-blocker tolerance com-
pared with the presence of a Sta-nrMFP pattern (p  0.21,
Figure 1. Schematic diagram of the titration profile of the patients enrolled in the study according to baseline mitral flow pattern (MFP) and its acute
change after loading manipulations. NTP  nitroprusside infusion; PLL  passive leg lifting.
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p  0.27 and p  0.45 for the three facets of tolerance).
That is to say that the two responses to loading maneuvers
had equivalent predictive value.
The two last columns of Table 3 give, respectively, the
goodness of the model in fitting the observed data (R2) and
the model’s overall predictive accuracy (AUC). Both indexes
markedly increased when the acute change of MFP after
loading manipulations was used in the model in place of
baseline MFP.
Baseline MFP and its changes induced by loading ma-
nipulations were also significantly associated with beta-
blocker dosage at the end of the titration phase (p 0.001).
All potential covariates were nonsignificant (p  0.2).
Corresponding coefficients of determination for the two
models were 0.1 and 0.3, respectively.
Effectiveness of beta-blocker treatment. At six months,
patients showed better NYHA functional class than they
did at baseline (NYHA I to II: 91% vs. 74%, NYHA III to
IV: 9% vs. 26%, p  0.001). An improvement in LVEF,
DT and mitral regurgitation according to the study criteria
(see Methods section) was observed, respectively, in 62%,
48% and 66% of the patients. Of the patients with a baseline
restrictive MFP, 31/43 (72%) moved to a nonrestrictive
MFP (chronic Rev-rMFP) and 12/43 (28%) did not change
MFP (chronic Irr-rMFP). Of the 31 patients, 30 (97%) had
a Rev-rMFP after loading manipulations at the start of the
study. Only one patient with an Irr-rMFP at the start of the
study had changed to having a nonrestrictive MFP at six
months. Of the patients with a baseline nonrestrictive MFP,
49/59 (83%) maintained a nonrestrictive MFP (chronic
Sta-nrMFP), and 10 (17%) worsened and moved to a
restrictive MFP (chronic Un-nrMFP). Six (60%) of the
latter had a Un-nrMFP after loading manipulations.
The association between either baseline MFP or its acute
change after loading manipulations and improvement in
LVEF, DT and mitral regurgitation after beta-blocker
treatment is presented in Table 4. Baseline MFP did not
provide any predictive information on the improvement in
LV performance and mitral regurgitation after beta-blocker
treatment. In contrast, the acute change in MFP after
loading manipulations showed a highly significant associa-
tion with all three aspects of beta-blocker treatment effec-
tiveness. It is worth emphasizing, in particular, that the
presence of a restrictive irreversible or nonrestrictive unsta-
ble pattern was a significant predictor of improvement in
LV performance and mitral regurgitation but not of im-
provement in DT, whereas the presence of a restrictive
reversible pattern acted in the opposite direction.
Clinical outcome. After 26  14 months (median 27
months) of follow-up, cardiac events had occurred in
23/102 (23%) patients. Congestive heart failure was the
cause of death in 4 (17%) patients; sudden death occurred in
Table 3. Association (Multivariate Logistic Regression Analysis) Between Either Baseline MFP or Its Acute Change After Loading
Manipulations and Tolerance to Beta-Blocker Treatment, Adjusting for Gender, Etiology, NYHA Class, LVEF and Peak VO2
Titration Interruption
Wald 2 p Value R2 AUC
Restrictive vs. nonrestrictive MFP 5.6 0.02 0.11 0.68
----------------------------------------------------------------------------------------------------------------------------------------------------------
Restrictive irreversible vs. nonrestrictive stable 11.3  0.001
Restrictive reversible vs. nonrestrictive stable 1.5 0.21 0.31 0.83*
Nonrestrictive unstable vs. nonrestrictive stable 3.2 0.07
Additional Examinations
Restrictive vs. nonrestrictive MFP 3.7 0.05 0.16 0.69
NYHA III to IV vs. I to II 4.0 0.04
----------------------------------------------------------------------------------------------------------------------------------------------------------
Restrictive irreversible vs. nonrestrictive stable 17.9  0.001
Restrictive reversible vs. nonrestrictive stable 1.2 0.27 0.45 0.84*
Nonrestrictive unstable vs. nonrestrictive stable 11.0  0.001
NYHA III to IV vs. I to II 3.7 0.05
Therapeutic Variations
Restrictive vs. nonrestrictive MFP 2.4 0.12 0.25 0.75
NYHA III to IV vs. I to II 11.0  0.001
----------------------------------------------------------------------------------------------------------------------------------------------------------
Restrictive irreversible vs. nonrestrictive stable 16.3  0.001
Restrictive reversible vs. nonrestrictive stable 0.6 0.45 0.49 0.85*
Nonrestrictive unstable vs. nonrestrictive stable 9.6 0.002
NYHA III to IV vs. I to II 10.6 0.001
*p  0.01 compared with AUC using baseline MFP.
The multivariate model for the association between MFP and beta-blocker tolerance is reported above the dashed line within each table, whereas the model for the association
between acute change of MFP after loading manipulations and beta-blocker tolerance is reported below the same line. The four responses to loading manipulations are coded
into three dichotomous variables representing response patterns: 1) restrictive irreversible, 2) restrictive reversible, and 3) nonrestrictive unstable relative to nonrestrictive stable
pattern.
AUC  area under the receiver operator characteristic curve; LVEF  left ventricular ejection fraction; MFP  mitral flow pattern; NYHA  New York Heart Association;
R2  generalized coefficient of determination; VO2  oxygen consumption.
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6 (26%) patients; 1 patient underwent urgent transplanta-
tion, and 12 (52%) developed congestive heart failure
requiring hospitalization. Among all variables considered as
potential predictors of the outcome including the chronic
change of MFP after six months of treatment, age, gender,
etiology, NYHA class, LVEF, peak VO2, baseline heart
rate and mean arterial pressure, only the chronic change of
MFP showed a significant association with the outcome in
Cox regression analysis. These results are summarized in
Table 5. Patients with chronic Rev-rMFP and Un-nrMFP
had a dramatically increased risk of events compared with
patients with chronic Sta-nrMFP. The latter, in turn, did
not show a significantly different risk with respect to
patients with chronic Rev-rMFP. The large CIs for the
relative risk are the effect of the small number of observa-
tions within each group, as reported in the first column of
Table 5. We also statistically compared the relative risk of
patients with Irr-rMFP with that of patients with Un-
nrMFP and found a largely nonsignificant result (p  0.5).
All these findings are graphically summarized by Kaplan-
Meier survival curves displayed in Figure 2. It can be seen
that the event-free survival function of patients with Irr-
rMFP is quite close to that of subjects with Un-nrMFP,
both curves being considerably separated from the curves of
the other two groups. The latter, in turn, show a modest
separation.
DISCUSSION
MFP findings: relation to beta-blocker titration manage-
ment and clinical benefits. Left ventricular systolic dys-
function in CHF is accompanied by concomitant LV
Table 4. Association (Multivariate Logistic Regression Analysis) Between Either Baseline MFP or Its Acute Change After Loading
Manipulations and Improvement in LVEF, Deceleration Time and Mitral Regurgitation After Six-Month Beta-Blocker Treatment,
Adjusting for Age, Gender, Etiology, NYHA Class, Baseline LVEF and Peak VO2
Improvement in LVEF
Wald 2 p Value R2 AUC
Restrictive vs. nonrestrictive MFP 0.24 0.62 — —
----------------------------------------------------------------------------------------------------------------------------------------------------------
Restrictive irreversible vs. nonrestrictive stable 7.1 0.008
Restrictive reversible vs. nonrestrictive stable 0.2 0.66 0.30 0.73
Nonrestrictive unstable vs. nonrestrictive stable 7.8 0.005
NYHA III to IV vs. I to II 4.5 0.03
Improvement in Deceleration Time
Restrictive vs. nonrestrictive MFP 10.7 0.001 0.20 0.72
Peak VO2 4.0 0.05
----------------------------------------------------------------------------------------------------------------------------------------------------------
Restrictive irreversible vs. nonrestrictive stable 1.2 0.26
Restrictive reversible vs. nonrestrictive stable 19.5  0.001 0.33 0.77
Nonrestrictive unstable vs. nonrestrictive stable 0.7 0.40
Improvement in Mitral Regurgitation
Restrictive vs. nonrestrictive MFP 0.04 0.84 — —
----------------------------------------------------------------------------------------------------------------------------------------------------------
Restrictive irreversible vs. nonrestrictive stable 7.3 0.007
Restrictive reversible vs. nonrestrictive stable 0.1 0.77 0.30 0.76
Nonrestrictive unstable vs. nonrestrictive stable 4.3 0.04
Peak VO2 4.0 0.04
The multivariate model for the association between MFP and the indexes of improvement in ventricular performance is reported above the dashed line within each table, whereas
the model for the association between acute change of MFP after loading manipulations and the same indexes is reported below the dashed line.
AUC area under the receiver operating characteristic curve; LVEF left ventricular ejection fraction; MFP mitral flow pattern; NYHA New York Heart Association;
R2  generalized coefficient of determination; VO2  oxygen consumption.
Table 5. Results of Survival Analysis (Cox Proportional Hazards Model) for the Combined End
Point: Cardiac Mortality  Urgent Heart Transplantation  Readmission for Congestive Heart
Failure
Chronic Change of
MFP Events Wald 2 p Value
Relative
Risk 95% CI
Restrictive irreversible 7/12 18.1  0.001 28.2 6–131
Restrictive reversible 5/31 2.0 0.16 2.8 0.7–12
Nonrestrictive unstable 8/10 24.8  0.001 50.0 11–233
Nonrestrictive stable 3/49 1
Variables in the model describe the chronic change of MFP after six months of beta-blocker treatment. Patients with a stable
nonrestrictive pattern represent the reference group.
CI  confidence interval; MFP  mitral flow pattern.
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diastolic dysfunction. Left ventricular filling patterns have
been shown to change over time in experimental and clinical
studies (12,28). Previous studies showed how MFP, evalu-
ated by echo-Doppler at baseline and after loading manip-
ulations, were strongly predictive of cardiac events (9–11).
This study pointed out that MFP, after acute loading
manipulations, could select subgroups of patients having
different clinical profiles and requiring different titration
management. Furthermore, MFP described the effect in-
duced by chronic beta-blocker therapy and the acquired
individual prognostic information.
In our experience carvedilol was well tolerated by patients
with heart failure; only 12% of patients had to be withdrawn
from the titration phase due to adverse events. These data
are consistent with the results of other studies that showed
a variable degree of intolerance (15,19,29). The rate of
withdrawal increases when the patients treated have severe
heart failure. Krum et al. (30) reported 49.5% of intolerance
in patients in NYHA functional class IV. In the study by
McDonald et al. (31), 43% of patients who were in NYHA
functional class IV experienced adverse events. However, in
about one-third of patients initially intolerant to carvedilol,
the drug could be reintroduced, and it produced clinical
benefits. This evidence gives rise to two important consid-
erations: 1) the titration phase of beta-blocker therapy can
be affected by adverse events that are time and cost-
consuming, 2) despite the rate of intolerance to beta-
blockers in patients with severe heart failure, in selected
subgroups carvedilol is a useful adjunctive therapy. Our
results showed that MFPs after loading manipulations were
more accurate than baseline MFP and NYHA functional
class in identifying patients who required different manage-
ment of carvedilol titration. In particular, we demonstrated
that 47% of patients who had an Irr-rMFP developed
adverse events requiring consequent therapy interruption;
the remaining subgroup tolerated treatment, but titration
management was complex, and, later, no clinical benefits
were demonstrable. In contrast, all those who had a Sta-
nrMFP tolerated carvedilol; management of the titration
was uncomplicated, and at six months the patients had more
clinical benefits. Patients with changes of MFP after loading
manipulations were in between these two extremes. In
particular, patients with a Un-nrMFP showed a signifi-
cantly more complex titration and tended to have more
likelihood of carvedilol interruption than patients with
Rev-rMFP after acute nitroprusside infusion. In contrast,
this last group of patients exhibited better clinical improve-
ment. The improvement of LV performance after chronic
therapy with carvedilol was concordant with the demon-
strated cardiovascular reserve during acute loading manip-
ulations. Ventricular remodeling and abnormal neurohor-
monal activity are time-dependent maladaptive processes in
response to myocardial injury (6). Previous studies have
shown how indexes of MFP are determined by complex
interactions of intrinsic characteristics of the heart such as
relaxation and chamber stiffness and extrinsic factors such as
loading manipulations (32–34). Baseline MFP and its
changes after loading manipulations may represent the
several steps of LV remodeling. Precisely, in our experience,
patients with a baseline nonrestrictive MFP had uncompli-
cated titration of carvedilol and derived most clinical ben-
efits. In this subgroup, abnormal relaxation was the predom-
inant factor conditioning ventricular filling with a concomitant
compensatory increase of the atrial contribution to filling. It is
likely that carvedilol in this subgroup improved intrinsic
ventricular properties such as abnormal relaxation and pre-
vented, by blockade of catecholamine actions, the remodeling
process (35). However, after leg lifting, 19% of these patients
Figure 2. Kaplan-Meier survival curves for the combined end point of cardiac mortality or urgent heart transplantation or readmission for congestive heart
failure. Patients were stratified according to the chronic change of the mitral flow pattern after six months of beta-adrenergic blocking agent treatment.
MFP  mitral flow pattern.
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acquired a restrictive filling pattern. It is likely that abnor-
malities of relaxation coexist with those of chamber stiffness.
Preload manipulation exposed changes in chamber stiffness,
which could have caused different titration of and clinical
benefits from carvedilol administration. At the other ex-
treme are the subgroups of patients with a baseline restric-
tive MFP who had a more complex titration management
and less clinical benefits from carvedilol titration than those
with a nonrestrictive MFP. However, after nitroprusside
infusion, 69% of these patients acquired a nonrestrictive
MFP. It is likely that LV remodeling had not affected chamber
stiffness in these patients but that they had unfavorable loading
conditions. In fact, nitroprusside, by preload, afterload and
mitral regurgitation reductions shifts the LV pressure/volume
curve leftward and downward with an improvement of early
diastolic filling (decrease of peak velocity, increase of DT)
and increases the atrial contribution to filling (36). Despite
the same dosage of nitroprusside, a subgroup of patients
maintained a restrictive MFP. This peripheral pooling effect
of nitroprusside unmasked an LV with increased chamber
stiffness. In this setting, the clinical surrogates were a complex
titration management and few clinical benefits. Overall, in
49/116 (42%) the patients’ baseline MFP or NYHA functional
class was not able to predict the response to or the clinical
effects of carvedilol administration. Changes of MFP after
loading manipulations, by revealing operative chamber stiff-
ness, restored the power of MFP to identify patients with
different responses to carvedilol administration.
Chronic changes of MFP after beta-blocker therapy:
trends and prognostic information. Another interesting
finding of this study is that, in patients with congestive heart
failure receiving chronic treatment with carvedilol, changes
of MFP identified by echo-Doppler were strongly related
with functional effects and gave important prognostic infor-
mation. Stevenson et al. (37) showed how forced unloading
therapy could induce marked clinical benefit. Although we
did not have a control group, in our previous experience,
long-term echo-Doppler monitoring of MFP in patients
with CHF and optimized therapy showed that, at six
months, the MFP moved from restrictive to nonrestrictive
in 28% and vice versa in 20% of patients (28). In contrast, in
patients who received carvedilol treatment, after six months
MFP shifted from restrictive to nonrestrictive in 72% and
vice versa in 17% of patients. These findings support the
role of beta-blockers in removing unfavorable loading con-
ditions and influencing LV remodeling. Previous studies
showed that a restrictive MFP was associated with increased
mortality in patients with CHF (9,10). Our study confirms
these findings and extends them, showing that, after titra-
tion, the changes of MFP are strongly associated with event
rates; so, in patients who moved after titration from a restrictive
MFP to a nonrestrictive MFP, the event rate decreased from
58% to 16%. Conversely, in patients who moved from a
nonrestrictive to a restrictive MFP, the event rate increased
from 6% to 80%. In addition, 15/23 (65%) hard events
occurred in patients who showed a restrictive MFP at six
months (Table 5). This has independent prognostic value by
Cox analysis.
Study limitations. The greatest limitation of this study is
that its results cannot be applied to patients with atrial
arrhythmias, a pacemaker or a prosthetic mitral valve.
Although echocardiographic measurements can be affected
by poor image quality or by interobserver variability, using a
cutoff value of reproducibility to evaluate a result as signif-
icant minimized the likelihood of these errors occurring.
Furthermore, potential abnormalities should have been
distributed evenly between the groups and, thus, would not
be expected to have altered the significance of the changes
found. The diastolic alterations were evaluated using Dopp-
ler variables, which may be affected by different factors (loading
conditions, heart rate) and cannot, therefore, be conclusive
about intrinsic diastolic function and the effects of carvedilol on
diastolic properties (relaxation rate and chamber stiffness). The
chronic evaluation at six months was an arbitrary choice
determined by the organization of follow-ups in our division.
In effect, the chronic control could be performed three months
after the end of the titration phase.
Conclusions. This study investigates the relationship be-
tween LV echo-Doppler monitoring and safety and efficacy
of long-term carvedilol therapy in patients with CHF.
Recent evidence showed that beta-blockers reduce mortality
and improve quality-of-life in patients with heart failure.
Patients who can profit from this effective and inexpensive
treatment are increasing; however, it has recently been
demonstrated that, in patients with CHF, the individual
response to beta-blocker therapy is highly variable in terms
of tolerance and efficacy, and most patients with severe heart
failure may be excluded from benefits of this useful therapy.
Our study shows that MFP and its changes after loading
manipulations may identify patients requiring different clin-
ical management during beta-blocker titration and deriving
different chronic benefits. Furthermore, echo-Doppler
MFP evaluated during chronic beta-blocker treatment pro-
vides a strong independent contribution to the assessment of
the risk of hard cardiac events. We believe that echo-Dopp-
ler monitoring of mitral flow at baseline and during loading
manipulations is an operative tool for managing beta-
blocker therapy in patients with CHF and for redefining
therapeutic strategies, including heart transplantation, in
those patients on chronic beta-blocker therapy.
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